Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

BPC-157 / TB-500 Blend (Dual Peptide)

0 Synergistic Pathways VEGF + Actin regulation 0+ Combined Studies BPC-157 (200+) + TB-500 (170+) 0% Faster Healing TB-500 re-epithelialization 0 Research Areas Tendon & Ligament · Wound Healing · Vascular Repair & more How It Works How BPC-157 / TB-500 works The pathways BPC-157 / TB-500 acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages. Signalling pathways studied in preclinical models · illustrative Angiogenesis & Cytoprotection BPC-157 BPC-157 upregulates VEGF expression and promotes new blood vessel formation, delivering nutrients and oxygen to damaged tissue. It also activates the NO system and demonstrates broad cytoprotective properties. VEGF-mediated angiogenesis Nitric oxide system modulation Gastric and tissue cytoprotection Cell Migration & Actin Regulation TB-500 TB-500 sequesters G-actin monomers and promotes cytoskeletal remodeling, enabling repair cells to migrate to injury sites. It also activates int

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

0

Synergistic Pathways

VEGF + Actin regulation

0+

Combined Studies

BPC-157 (200+) + TB-500 (170+)

0%

Faster Healing

TB-500 re-epithelialization

0

Research Areas

Tendon & Ligament · Wound Healing · Vascular Repair & more

How It Works

How BPC-157 / TB-500 works

The pathways BPC-157 / TB-500 acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.

Signalling pathways studied in preclinical models · illustrative

Angiogenesis & Cytoprotection

BPC-157

BPC-157 upregulates VEGF expression and promotes new blood vessel formation, delivering nutrients and oxygen to damaged tissue. It also activates the NO system and demonstrates broad cytoprotective properties.

VEGF-mediated angiogenesis Nitric oxide system modulation Gastric and tissue cytoprotection

Cell Migration & Actin Regulation

TB-500

TB-500 sequesters G-actin monomers and promotes cytoskeletal remodeling, enabling repair cells to migrate to injury sites. It also activates integrin-linked kinase (ILK) for tissue repair signaling.

Actin-mediated cell migration Integrin-linked kinase activation Anti-fibrotic remodeling

Complementary Repair Cascade

Synergy

BPC-157 initiates vascular support (blood flow to injury), while TB-500 mobilizes repair cells to the site. Together they address two distinct phases of tissue repair — perfusion and cellular migration.

Phase 1: Blood flow restoration (BPC-157) Phase 2: Cell mobilization (TB-500) Combined anti-inflammatory effects

Uses & Applications

What BPC-157 / TB-500 is researched for

The main areas BPC-157 / TB-500 is being studied for — and the study-reported figures behind them. Musculoskeletal

Tendon & Ligament

BPC-157 accelerates tendon healing while TB-500 enhances cell migration to the injury site for coordinated soft tissue repair.Chang et al. 2014 Dermatology

Wound Healing

TB-500 promotes dermal healing and reduces scarring; BPC-157 provides vascular support for nutrient delivery to wound sites.Malinda et al. 2007 Cardiovascular

Vascular Repair

BPC-157 promotes angiogenesis via the NO system while TB-500 supports cardiac cell migration through ILK activation.Sikiric et al. 2019 Anti-Inflammatory

Inflammation Control

Both peptides demonstrate anti-inflammatory properties through distinct mechanisms, creating a more controlled healing environment.Sikiric et al. 2011

Study-reported magnitudes

Representative figures from published research. Bars fill as you scroll.

BPC-157 Tendon Healing72%

TB-500 Cell Migration85%

BPC-157 GHR Expression700%

TB-500 Wound Closure61%

Figures are representative of published research findings and shown for reference.

Molecular Structure

The BPC-157 / TB-500 molecule

An interactive 3D model rendered from the compound record — rotate and explore its structure.

Molecular model

Sequence length blend

Physical form Lyophilized powder blend

Documented purity ≥99% by HPLC

Third-Party Verified

Independently tested. Verifiably pure.

Every batch of BPC-157 / TB-500 is sent to an accredited independent laboratory before it ships. Here is what we screen for.

HPLC Purity AnalysisConfirms the peptide is ≥99% pure

Mass SpectrometryVerifies the exact molecular identity

Heavy Metals ScreeningLead, arsenic, cadmium & mercury — Pass

Endotoxins (LAL)Bacterial endotoxin levels — Pass

Sterility TestingNo microbial contamination — Pass

Net Peptide ContentActual peptide mass per vial verified

Certificate of Analysis · Freedom DiagnosticPASS

HPLC Purity ≥99%

Identity Mass-spec confirmed

Endotoxin (LAL) Pass

Net content Verified

Compound Information

Full specification

Components BPC-157 + TB-500 (Thymosin Beta-4) BPC-157 Sequence 15 amino acids (Gly-Glu-Pro-Pro-Pro...) TB-500 Fragment 43-amino acid active region of Tβ4 Form Lyophilized powder blend Purity ≥99% per component (HPLC verified) Testing Third-party HPLC, Mass Spec, Endotoxin Storage (Lyophilized) -20°C for long-term stability Storage (Reconstituted) 2–8°C, use within 14-21 days Solubility Bacteriostatic water for reconstitution COA Included with every order Strength 20mg Purity (HPLC) >99% (HPLC) Appearance White to off-white powder Stability 24 months from manufacture date when stored properly

FAQ

Common questions about BPC-157 / TB-500

BPC-157 and TB-500 target complementary repair mechanisms. BPC-157 promotes blood vessel formation (angiogenesis) to deliver nutrients to injured tissue, while TB-500 mobilizes repair cells through actin regulation. Together they address both vascular support and cellular migration phases of tissue repair.

No. The combination has not been studied as a single formulation in clinical trials. The synergy rationale is based on complementary mechanisms from individual component research (200+ BPC-157 studies, 170+ TB-500 studies). Both are well-studied individually in preclinical models.

No. Neither BPC-157 nor TB-500 is FDA approved for any indication. This blend is sold exclusively for in vitro laboratory research purposes and is not intended for human consumption.

Store lyophilized at -20°C for long-term stability. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 14-21 days. Both components maintain stability under standard peptide storage conditions.

Each component undergoes independent third-party testing including HPLC for purity verification, mass spectrometry for molecular weight confirmation, and endotoxin testing. A Certificate of Analysis is included with every order.

Published Literature

Cited Sources

Peer-reviewed literature

Independent published research indexed from PubMed and peer-reviewed journals — not Eon Peptides claims.

For Research Use Only.

Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.

Connected topics

Follow this recovery question